ProKidney Corp. (NASDAQ:PROK) SVP Sells $145,498.19 in Stock

ProKidney Corp. (NASDAQ:PROK) SVP Darin J. Weber sold 84,103 shares of the company’s stock in a transaction on Friday, April 12th. The stock was sold at an average price of $1.73, for a total transaction of $145,498.19. Following the transaction, the senior vice president now directly owns 189,670 shares in the company, valued at $328,129.10. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

ProKidney Stock Down 15.0 %

NASDAQ:PROK opened at $2.04 on Friday. ProKidney Corp. has a fifty-two week low of $1.12 and a fifty-two week high of $13.51. The firm’s fifty day simple moving average is $1.60 and its 200-day simple moving average is $1.79. The stock has a market cap of $467.85 million, a PE ratio of -3.58 and a beta of 1.08.

ProKidney (NASDAQ:PROK) last released its quarterly earnings data on Thursday, March 21st. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.19) by $0.10. Equities analysts anticipate that ProKidney Corp. will post -0.65 earnings per share for the current year.

Analyst Ratings Changes

PROK has been the topic of a number of recent analyst reports. Morgan Stanley initiated coverage on shares of ProKidney in a research note on Thursday, March 7th. They set an “equal weight” rating and a $3.00 price target on the stock. Bank of America cut shares of ProKidney from a “buy” rating to a “neutral” rating in a research note on Tuesday, January 2nd.

Institutional Investors Weigh In On ProKidney

Several institutional investors and hedge funds have recently made changes to their positions in the business. Morgan Stanley boosted its position in shares of ProKidney by 5.8% in the 4th quarter. Morgan Stanley now owns 10,947,495 shares of the company’s stock worth $75,100,000 after buying an additional 595,839 shares in the last quarter. BlackRock Inc. boosted its position in shares of ProKidney by 978.2% in the 2nd quarter. BlackRock Inc. now owns 3,316,973 shares of the company’s stock worth $37,117,000 after buying an additional 3,009,342 shares in the last quarter. Vanguard Group Inc. lifted its holdings in ProKidney by 7.5% in the 3rd quarter. Vanguard Group Inc. now owns 3,291,859 shares of the company’s stock valued at $15,077,000 after purchasing an additional 229,078 shares in the last quarter. State Street Corp lifted its holdings in ProKidney by 1,540.0% in the 2nd quarter. State Street Corp now owns 990,259 shares of the company’s stock valued at $11,081,000 after purchasing an additional 929,878 shares in the last quarter. Finally, Geode Capital Management LLC lifted its holdings in ProKidney by 450.9% in the 2nd quarter. Geode Capital Management LLC now owns 760,823 shares of the company’s stock valued at $8,514,000 after purchasing an additional 622,728 shares in the last quarter. 51.59% of the stock is currently owned by hedge funds and other institutional investors.

ProKidney Company Profile

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease.